Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

By R. Gadaleta, K. V. van Erpecum, B. Oldenburg, E. C. Willemsen, W. Renooij, S. Murzilli, L. Klomp, Peter D. Siersema, M. Schipper, S. Danese and 5 more. Gut, 2011

792 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/a235cb74b199be9f68cf9f43ef829e0a1507efec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Natascha Roehlen
2. Mathieu Vinken
3. E. Crouchet
4. T. Baumert

In Oncology

1. J. Y. Chiang
2. Christoph Borner
3. Hanns-Ulrich Marschall
4. S. Ghosh
5. David S. Wishart

Citations in the corpus

• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “These downstream elements then regulate the expression levels of pro-fibrotic target genes such as type I collagen (COL1A1), metalloproteinase inhibitors (TIMPs), and MMPs but also the apoptosis regulator Bcl 2, resulting in cell proliferation and survival [17].”
• Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013, background): “Interestingly, OCA also enhances colonic expression of cathelicidin, a natural antibiotic with microbicidal properties, suggesting its capacity to modulate the gut microbiota.(48) The gut microbiota has recently been shown to influence the size and composition of the bile acid pool throughout the en”
• Understanding the Holobiont: How microbial metabolites affect human health and shape the immune system (2017, background): “Correspondingly, treatment with a synthetic agonist of BAR has protective effects in mouse models of colitis, whereas BAR-deficient (Nr1h4 / ) mice exhibit exacerbated pathology (Gadaleta et al., 2011; Vavassori et al., 2009).”
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013, positive): “Treatment of isolated human mononuclear cells with the FXR agonist obeticholic acid (INT- 747) decreased TNFa secretion and prevented differentiation of CD14? monocytes into dendritic cells (Gadaleta et al. 2011).”
• Bile Acid Metabolism and Signaling (2013, positive): “OCA antagonizes NF-κB-stimulated inflammation in liver (203), modulates innate immunity in animal models of colitis (197), inhibits and preserves the intestinal barrier in inflammatory bowel disease (69), and inhibits vascular smooth muscle cell inflammation and migration (119).”
• Pathological bacterial translocation in liver cirrhosis. (2014, background): “Conjugated bile acids are natural ligands for several nuclear receptors, of which the transcription factor farnesoid X receptor (FxR) has gained much attention [75].”